Clinical Trials

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Lymphoma, Mantle-Cell

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

2 enrolled

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT03697356 2023-10-06

Ballondor

Phase 2 Recruiting

54 enrolled

Waldenstrom Macroglobulinemia

NCT00571493 2023-09-28

VELCADE®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma, or Mantle Cell Lymphoma

Phase 1/2 Completed

42 enrolled 8 charts

Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell

NCT01267812 2023-07-27

Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation

23 enrolled 10 charts

Lymphoma, Mantle-Cell

NCT02840539 2023-03-20

BATMAN

19 enrolled

Lymphoma, Mantle-Cell

NCT02356458 2022-03-11

Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma

Phase 1/2 Terminated

58 enrolled

Lymphoma, Neoplasms, Recurrence, Lymphoma, Mantle-Cell

NCT00477412 2022-01-28

Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma

Phase 1/2 Completed

107 enrolled 14 charts

Lymphoma, Mantle-Cell

NCT02613598 2021-12-20

Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma

Phase 1 Completed

15 enrolled

Hodgkin Disease, Lymphoma, Non-Hodgkin

NCT00479167 2021-11-04

A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma

Phase 2 Terminated

1 enrolled 1 chart

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin

NCT01592981 2021-06-18

R2W

60 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Waldenstrom Macroglobulinemia

NCT02037256 2021-05-10

Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma

Phase NA Completed

23 enrolled 8 charts

Burkitt Lymphoma, Leukemia, Hairy Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Intraocular Lymphoma

NCT01046006 2021-04-30

Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's Macroglobulinemia

59 enrolled

Lymphoma, Waldenstrom Macroglobulinemia

NCT01125293 2021-04-23

Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia

Phase 1/2 Terminated

46 enrolled 29 charts

Waldenstrom Macroglobulinemia

NCT00422799 2020-10-27

Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia (WM)

63 enrolled 10 charts

Waldenstrom Macroglobulinemia

NCT01965977 2020-10-23

Borma

Phase 2 Unknown

59 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT03515200 2020-09-01

Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia

Phase 1 Terminated

12 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00182637 2020-08-03

Bortezomib in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma

5 enrolled 4 charts

DermatologicLymphoid

Lymphoma, Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT03617484 2020-06-22

Bortezomib in Combination With Ibrutinib in Ibrutinib Relapsed Mantle Cell Lymphoma

Phase 2 Withdrawn

Recurrence, Lymphoma, Mantle-Cell

NCT00980395 2019-12-30

VCR

24 enrolled 11 charts

Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT00581776 2019-12-17

Phase II Study of VcR-CVAD With Rituximab Consolidation and Maintenance for Untreated Mantle Cell Lymphoma

30 enrolled 10 charts

Lymphoma, Mantle-Cell

NCT00439556 2019-09-10

Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplant

40 enrolled 11 charts

Lymphoma, Hematologic Neoplasms

NCT04061772 2019-08-20

A Study of Bortezomib Combined With CHEP in Peripheral T Cell Lymphoma

Phase 2 Unknown

54 enrolled

Lymphoma, T-Cell, Peripheral

NCT02535806 2019-08-13

Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults

Phase 2 Terminated

2 enrolled 11 charts

Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01111188 2019-06-27

Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell Lymphoma

Phase 1 Terminated

20 enrolled

DermatologicLymphoidOther hematologic neoplasm

Lymphoma, Mantle-Cell

NCT00290706 2019-05-28

A Phase I/II Trial of VELCADE & Gemcitabine for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma

Phase 1/2 Terminated

32 enrolled 12 charts

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Mycosis Fungoides, Sezary Syndrome, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01164709 2019-05-15

Nelfinavir Mesylate and Bortezomib in Treating Patients With Relapsed or Progressive Advanced Hematologic Cancer

Phase 1 Completed

18 enrolled

DermatologicLymphoidOther hematologic neoplasmPlasma cell

Congenital Abnormalities, Hodgkin Disease, Immunoblastic Lymphadenopathy, Leukemia, Lymphoma, Lymphoma, Follicular, Multiple Myeloma, Mycosis Fungoides, Sezary Syndrome, Leukemia, Prolymphocytic, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Mantle-Cell, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell, Lymphoma, Extranodal NK-T-Cell

NCT00711828 2019-04-16

Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma

21 enrolled 10 charts